While the pharmaceutical industry is heavily regulated to ensure medication safety, these regulations should not hinder ...

UK digital health company RHYTHM AI has claimed FDA approval for a new version of its algorithm for mapping areas of the ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

Zevra Therapeutics' Miplyffa has become the first medicine to be approved by the FDA for the ultra-rare genetic disorder ...

J&J said its latest bankruptcy bid is backed by around 83% of the 60,000-plus claimants cited in lawsuits, who are claiming ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Shares in Neurocrine Biosciences took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

The Medtech sector is currently at a crossroads, facing a potential choice between rapid technological advancement and strict regulatory oversight. To realise the full impact of AI and the value ...

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media reports.

A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals participating in the 340B programme for healthcare systems serving ...

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024. The panel ...